#Paris #France #Velico #veliPod #BloodTransfusion

A Revolutionary Step in Blood Transfusion Technology

On February 17, 2026, a landmark achievement occurred at the Armed Forces Blood Transfusion Centre (CTSA) located in Paris, France. This pivotal moment was marked by the introduction of Velico Medical's first veliPod™, a containerized spray-dried plasma manufacturing system. This innovative technology is revolutionizing the production of blood products and signifies an advancement towards decentralized manufacturing in military and emergency medical settings.

What is the veliPod™?

The veliPod™ represents a modular solution, designed to fit within the constraints of traditional infrastructures, such as military bases and blood centers. Its unique design not only accommodates rapid deployment but also promotes scalability, allowing for immediate adaptation to diverse operational environments. This system relies solely on water and electricity, making it suitable for clean and mobile environments without necessitating the use of heavy infrastructure, such as clean rooms.

According to Dr. Jean-Jacques Lataillade, the Chief Medical Officer at CTSA, the compact design of the veliPod™ allows for the production of spray-dried plasma in less than three minutes, significantly expediting the transfusion process. This capability is crucial, especially in trauma care where uncontrolled bleeding remains a leading cause of preventable death globally.

Transforming Trauma Care

The deployment of Velico’s FrontlineODP™ system allows for the transformation of liquid plasma into a stable, ultra-lightweight powder that can be stored at ambient temperatures. This advancement in medical technology eliminates the need for strict cold chain management typically associated with traditional plasma storage. Consequently, this increases accessibility in remote, military, and emergency settings where logistics can pose a serious barrier to timely medical interventions.

By enabling on-site production, the veliPod™ opens up possibilities for nations to develop self-sufficiency in producing critical blood products, ultimately enhancing preparedness for mass casualty events, natural disasters, and military operations. There remains a considerable global deficit in the production of spray-dried plasma—less than 50,000 units are produced annually compared to the over 10 million units needed during World War II. This gaping disparity highlights the urgent need for scalable local manufacturing solutions, particularly in the current geopolitical climate.

Meeting Urgent Global Needs

The veliPod™ aims to bridge the supply-demand gap by facilitating production of up to 9,000 units annually. Richard Meehan, President and CEO of Velico, emphasized that France's adoption of the veliPod™ sets a pioneering precedent for national preparedness, resilience, and innovation in trauma care. The system reinforces the imperative for nations to bolster local physiological capabilities, thereby better equipping medical responders to handle emergencies efficiently.

Clinical Trials and Future Directions

Velico’s FrontlineODP™ has shown promising results in initial clinical stage testing with a strong safety profile evidenced by the absence of serious adverse events. These early findings underscore the technology’s potential to redefine both civilian and military medical practices. In alignment with its vision of reducing avoidable mortality from hemorrhage, Velico is poised to revolutionize emergency healthcare through its pioneering technology.

As the veliPod™ is operational in France, it could pave the way for broader acceptance and application of decentralized plasma manufacturing across borders. This innovative leap is set to drastically augment the medical capabilities of military personnel and first responders alike.

Conclusion

In summary, the introduction of Velico's veliPod™ at the Armed Forces Blood Transfusion Centre in Paris not only marks a significant milestone in blood transfusion innovation but also creates a basis for national resource independence. With its implementation, the French military stands ready to tackle global plasma shortages while also contributing invaluable advancements in trauma care methodologies. This breakthrough could lay the groundwork for future collaborations in developing sustainable blood product solutions worldwide.